CADL
CADL clinical trials: Candel Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Candel Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 14
- Trials linked
- 13
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
CADL on the catalyst calendar · CADL registry changes
- Primary completion Dec 31, 2024ActualPhase 2NCT04495153CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLCCandel Therapeutics, Inc. · Non Small Cell Lung CancerActive, not recruitingCADLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2024ActualPhase 2NCT02768363Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)Candel Therapeutics, Inc. · Prostate CancerActive, not recruitingCADLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2024ActualPhase 3NCT01436968Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate CancerCandel Therapeutics, Inc. · Prostate CancerActive, not recruitingCADLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2027Sponsor estimatePhase 2NCT07332000A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene BesadenovecCandel Therapeutics, Inc. · Prostate Cancer Patients Treated by RadiotherapyRecruitingCADLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 22, 2031Sponsor estimatePhase 3NCT07660094Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)Candel Therapeutics, Inc. · Non-squamous, Non-Small Cell Lung CancerRecruitingCADLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2021ActualPhase 1NCT03131037Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung CancerCandel Therapeutics, Inc. · Lung CancerCompletedCADLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2023ActualPhase 1NCT03576612GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade GliomasCandel Therapeutics, Inc. · Glioma, MalignantCompletedCADLLeadBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2015ActualPhase 2NCT00589875Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant GliomaCandel Therapeutics, Inc. · Malignant GliomaCompletedCADLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2025Sponsor estimatePhase 2NCT02446093Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic AdenocarcinomaCandel Therapeutics, Inc. · Borderline Resectable Pancreatic AdenocarcinomaUnknown statusCADLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2015ActualPhase 1NCT01997190Intrapleural AdV-tk Therapy in Patients With Malignant Pleural EffusionCandel Therapeutics, Inc. · Malignant Pleural EffusionCompletedCADLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2010ActualPhase 1NCT00751270Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant GliomasCandel Therapeutics, Inc. · Malignant GliomaCompletedCADLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2013ActualPhase 1NCT00638612AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)Candel Therapeutics, Inc. · Pancreatic AdenocarcinomaCompletedCADLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2015ActualPhase 1NCT00634231A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain TumorsCandel Therapeutics, Inc. · Malignant GliomaCompletedCADLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimatePhase 1NCT03152318A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2Dana-Farber Cancer Institute · Malignant Glioma of BrainActive, not recruitingCADLCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 14 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner